Anti-inflammatory activity of palmitoylethanolamide ameliorates osteoarthritis induced by monosodium iodoacetate in Sprague-Dawley rats
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- Sprague-Dawley rats with monosodium iodoacetate (MIA)-induced osteoarthritis, in normal, MIA-control, PEA 50 mg/kg, PEA 100 mg/kg and diclofenac groups
- Dose used in the study
- PEA 50 or 100 mg/kg body weight per day, oral
- Duration
- Not stated in the abstract
- What was measured
- Body weight, liver and kidney safety markers, knee joint swelling and cartilage degradation, blood inflammatory mediators, and gene expression of inflammatory mediators and cytokines in the synovium.
What the authors reported
The laboratory study found:
- Oral PEA caused no adverse effects on body weight, liver or kidneys.
- PEA reduced knee joint swelling and cartilage degradation.
- The 100 mg/kg dose lowered serum leukotriene B4, nitric oxide, TNF-alpha, IL-1beta and prostaglandin E2.
- It also reduced synovial iNOS, 5-Lox, Cox-2, Il-1beta, Tnf-alpha and Mmp-2/-3/-9/-13 mRNA, and increased Timp-1 mRNA toward normal levels.
Limits of this study
A rat model of chemically induced osteoarthritis; it cannot show effect in people or animals treated in practice. The authors declare no conflicts of interest.
Source
PubMed 34468900 · doi:10.1007/s10787-021-00870-3
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.